Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-1,3-glucan-binding protein (BGBP) is a critical pattern recognition receptor (PRR) that facilitates the innate immune system's detection of fungal and certain bacterial pathogens by specifically identifying beta-1,3-glucans, which are major structural components of fungal cell walls (MDPI, PMC3056088). In invertebrates, such as crustaceans and insects, BGBP is typically a soluble protein found in the hemolymph that initiates essential immune cascades, including the prophenoloxidase (proPO) activation system and the Toll signaling pathway (UniProt, PubMed 20111166). In mammals, this functional role is performed by membrane-bound receptors, most notably Dectin-1 (CLEC7A) and Complement Receptor 3 (CR3), which are expressed on myeloid cells like macrophages, dendritic cells, and neutrophils (PMC7911664). Binding of beta-glucan ligands to these receptors induces receptor clustering and activates downstream intracellular signaling cascades, such as the Syk/NF-κB pathway, leading to the production of pro-inflammatory cytokines, the generation of reactive oxygen species (ROS), and enhanced phagocytic activity (Frontiers in Immunology). Therapeutically, BGBP and its functional equivalents are targeted by various beta-glucan compounds, including lentinan, schizophyllan, and Imprime PGG, which are being investigated for their potential to 'prime' the immune system in cancer immunotherapy and as adjuvants for infectious diseases (PMC6479769, MDPI).
Receptor agonism; binding of beta-1,3-glucan ligands induces receptor clustering and initiates signaling cascades (e.g., proPO in invertebrates or Syk/NF-κB in mammals) to stimulate innate immune effector functions.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-1,3-glucan-binding protein (BGBP).